GlaxoSmithKline files its arguments to Supreme Court of Canada
September 19, 2011
GlaxoSmithKline (GSK) has filed its case facts with the Supreme Court of Canada refuting arguments made by the Crown in this precedent-setting transfer pricing case, involving the price of the active ingredient used to make the drug sold under the brand name Zantac.
The Canada Revenue Agency had assessed GSK on the grounds that the price paid for the active ingredient was significantly higher than generic counterparts.
Sorry. You must be a subscriber to view this article. Alternatively, why not take a free trial? To subscribe and access this article immediately simply click here or call +44(0)207 779 8380.